CMR rates, strategies, and CAR-T data in high-grade lymphoma

The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific monoclonal antibodies, there is hope for a wider demographic of patients.

Due to the COVID-19 pandemic, the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually – and it didn’t disappoint in the quality and breadth of data presented.

In this exclusive discussion leading experts Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK debate the latest in the treatment of lymphoma from the ASH 2020 virtual Annual Meeting and share how the new research and clinical updates can help improve patient management strategies in UK clinical practice.

The post The Lymphoma Sessions: ASH 2020 highlights appeared first on VJHemOnc.